A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms

NCT00817986 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

161

Enrollment

INDUSTRY

Sponsor class

Conditions

Back Pain

Interventions

DRUG: Arbaclofen placarbil, 20 mg
DRUG: Placebo
DRUG: Arbaclofen placarbil, 30 mg
DRUG: Arbaclofen placarbil, 40 mg

Sponsor

XenoPort, Inc.